R2T Biopharma

R2T Biopharma is an innovative nutraceutical and biotechnology company that specializes in two main areas: advanced nutritional supplements using liposomal drug delivery technology and therapeutic cancer vaccines. The company's name stands for "Right to Try," inspired by the federal legislation that allows patients with life-threatening conditions access to experimental treatments. The company's proprietary liposomal drug delivery system transforms nutrients into biocompatible nano-size particles to significantly increase body absorption rates. Unlike traditional liposomal formulations based on lecithin, R2T's technology utilizes olive leaf extracts, which provides higher potency. The lipid bilayer of their liposomes can fuse with cell membranes throughout the body, allowing for targeted delivery of encapsulated nutrients while protecting them from degradation in various bodily environments. R2T's commercial liposomal supplements demonstrate 4-5 times higher body absorption rates compared to conventional capsules and tablets. These products target multiple therapeutic areas including aging prevention, inflammatory conditions, dementia, and cancer support. The company has expanded into oncology therapeutics through its acquisition of Xeme Biopharma Inc., gaining access to Aggregon, a therapeutic cancer vaccine platform. This vaccine technology is designed to be customized, rapidly produced, easy to administer, non-toxic, and safe for both hematologic cancers and solid tumors. This approach addresses limitations of traditional cancer therapies, which often involve trade-offs between specificity, toxicity, and efficacy, and typically cannot eliminate residual cancer cells, leading to tumor relapse.